10-Q: CERO Therapeutics Q3 2025: Delisting, Losses, and Funding Challenges

CERO Therapeutics reported a significant increase in net loss for Q3 2025, faced Nasdaq delisting, and continues to rely on further capital raises to fund its early-stage clinical development.

Summary

• Net loss attributable to common shareholders increased significantly to $(11.5) million for the three months ended September 30, 2025, and $(47.1) million for the nine months ended September 30, 2025.
• The company was delisted from Nasdaq on October 31, 2025, and its shares commenced trading on the OTC Pink Sheets.
• Cash and cash equivalents were $2.02 million as of September 30, 2025, with an accumulated deficit of $86.3 million, raising substantial doubt about the company's ability to continue as a going concern.
• Research and development expenses increased to $2.39 million for Q3 2025 and $8.05 million for the nine months, driven by clinical expenses, scientific consulting, and drug manufacturing.
• General and administrative expenses decreased to $1.98 million for Q3 2025 and $5.99 million for the nine months, primarily due to reduced professional fees.
• The company initiated a Phase 1/1b trial for its lead compound, CER-1236, in acute myelogenous leukemia (AML), dosing the first patient in May 2025 and the third patient in September 2025.
• CER-1236 received FDA Orphan Drug Designation in June 2025 and Fast Track Designation in September 2025 for AML.
• A second Investigational New Drug (IND) application for CER-T cell therapy in NSCLC and ovarian cancer was accepted by the FDA on March 27, 2025.
• The company raised approximately $4.2 million net proceeds from a public offering in February 2025, $4.2 million from Series A Preferred Warrants exercise, stock subscriptions, and ELOC fundings, and $2.6 million from Series D Preferred Stock sales during the nine months ended September 30, 2025.
• Subsequent to Q3, the company raised approximately $2.25 million from Series E Preferred Stock in October 2025 and $1.54 million from the New Keystone Purchase Agreement through November 19, 2025.
• Material weaknesses in internal control over financial reporting were identified, including insufficient personnel with technical accounting expertise, inadequate processes for preferred stock conversions, and deficiencies in equity securities valuation.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a rapidly increasing net loss, significant accumulated deficit, and a 'going concern' warning. The Nasdaq delisting is a major setback, impacting liquidity and future capital-raising ability. The identified material weaknesses in internal controls and a history of untimely SEC filings further undermine confidence. While clinical and regulatory milestones are positive, they are overshadowed by critical financial and operational challenges.

Positives

• FDA Orphan Drug Designation was granted to CER-1236 for the treatment of AML in June 2025.
• FDA Fast Track Designation was granted to CER-1236 for AML in September 2025, potentially accelerating development and review.
• The first patient was dosed with CER-1236 in a Phase 1/1b trial for AML in May 2025, with initial evaluation of the first patient showing no dose-limiting toxicity.
• A second Investigational New Drug (IND) application for CER-T cell therapy in NSCLC and ovarian cancer was accepted by the FDA on March 27, 2025.
• Successful capital raises totaling approximately $13.2 million during the nine months ended September 30, 2025, and an additional $3.79 million post-quarter, providing necessary, albeit insufficient, funding.

Negatives

• The company was delisted from the Nasdaq Stock Market on October 31, 2025, and its shares commenced trading on the OTC Pink Sheets, which is a less liquid market.
• Net loss attributable to common shareholders increased significantly by 172.1% to $(11.5) million for Q3 2025 and by 424.5% to $(47.1) million for the nine months ended September 30, 2025, compared to prior year periods.
• Cash and cash equivalents decreased to $2.02 million as of September 30, 2025, from $3.33 million at December 31, 2024.
• An accumulated deficit of approximately $86.3 million as of September 30, 2025, raises substantial doubt about the company's ability to continue as a going concern within one year.
• Material weaknesses were identified in internal control over financial reporting, including insufficient personnel with technical accounting expertise, inadequate processes for preferred stock conversions, and deficiencies in equity securities valuation.
• Deemed dividends on Series A, B, C, and D Preferred Stock totaling $31.6 million and $6.65 million respectively, and $84,000 related to Series C Common Warrants, significantly increased the net loss attributable to common shareholders.
• A $500,000 write-off of deferred offering costs related to the Arena ELOC was recorded due to the unlikelihood of raising funds through that agreement.

Risks

• Inability to raise additional capital to fund research and development (R&D) activities and meet obligations, potentially leading to significant spending reductions, delays, or cancellation of planned activities.
• Risks inherent in an early-stage biotechnology company, including limited management resources, intense competition, and dependence upon the availability of cash to sustain operations.
• Uncertainty of obtaining FDA approvals for current ongoing research and future clinical development, which could materially adversely affect future financial results and cash flows.
• Nasdaq delisting could limit investors' ability to make transactions, reduce liquidity, potentially lead to a 'penny stock' designation, limit news and analyst coverage, and decrease the ability to issue additional securities or obtain financing.
• The issuance of shares of common stock upon conversion or exercise of outstanding preferred stock, warrants, and other securities may result in substantial dilution to stockholders, especially with down-round provisions and penalties.
• Disruptions at the FDA, SEC, and other government agencies (e.g., staffing reductions, funding shortages, government shutdowns) could hinder timely regulatory reviews and approvals, impacting business operations.
• The impact of recent healthcare reform legislation (e.g., Medicare Drug Price Negotiation Program, OBBBA changes to Medicaid) on future revenue prospects, pricing, and reimbursement is unknown and may adversely affect the business model.
• Risks associated with tariffs and other trade restrictions, including potential increases in R&D expenses due to higher costs for raw materials, equipment, and components.
• Changes in tax laws or regulations (e.g., Section 174 of the Code) that are applied adversely could have a material adverse effect on business, cash flow, financial condition, or results of operations.
• Failure to effectively remediate identified material weaknesses in internal control over financial reporting could impair the ability to produce timely and accurate financial statements or comply with applicable laws and regulations, leading to sanctions or investigations.

Future Outlook

The company anticipates a significant increase in R&D expenses as it continues preclinical and clinical development and manufacturing of its product candidates. It also expects to incur additional costs associated with operating as a public company. Substantial additional funding will be needed to maintain current operations and R&D activities, but there is no assurance that sufficient funding will be available. The recent delisting from Nasdaq is expected to make future capital raises more difficult, potentially leading to significant reductions in spending or the delay/cancellation of planned activities.

Management Comments

• "The Companys ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development (R&D) activities and meet its obligations on a timely basis."
• "However, there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned regulatory filings with the FDA."
• "If the Company is unable to obtain the necessary funds, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Companys business, results of operations, and prospects."
• "These conditions raise substantial doubt about the Companys ability to continue as a going concern within one year from the date these financial statements are issued."
• "The Company anticipates that its R&D expenses will significantly increase in the future as the Company increases headcount, compensation expense, and contracted services for preclinical and clinical development of its product candidates, as well as for manufacturing of clinical product to be used in clinical development."

Industry Context

The company operates in the highly competitive and capital-intensive early-stage biotechnology sector. The challenges faced, such as the continuous need for capital raises, significant R&D expenses, and regulatory hurdles, are typical for companies in this stage. The Nasdaq delisting highlights the increased scrutiny and difficulty for pre-commercialization biotech companies to maintain public listing standards, especially amidst challenging equity capital markets. Healthcare reform legislation and trade restrictions add further uncertainty to future revenue and operational costs, impacting the entire industry.

Comparison to Industry Standards

• The company's accumulated deficit of $86.3 million and reliance on continuous capital raises are common for early-stage biotech companies, which typically operate at a loss for extended periods during drug development, similar to many pre-revenue biopharmaceutical firms.
• The FDA Orphan Drug and Fast Track designations for CER-1236 in AML are positive regulatory milestones, comparable to achievements by other biotech firms developing therapies for rare or serious conditions, potentially offering market exclusivity and accelerated review, aligning with industry efforts to expedite drug development for unmet needs.
• The Nasdaq delisting, however, places the company at a significant disadvantage compared to peers maintaining listing on major exchanges, impacting liquidity and access to capital, which is a critical differentiator in the biotech funding landscape.
• The identified material weaknesses in internal controls are a significant concern, indicating a deviation from best practices for public companies, unlike well-established industry players that typically maintain robust financial reporting systems.

Management Changes

Corporate Governance

Legal Proceedings

• As of September 30, 2025, the company does not believe it is party to any claim or litigation the outcome of which, if determined adversely, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business.

Related Party Transactions

• Daniel Corey (former CTO and board member) purchased 150 shares of Series A Preferred Stock for $150,000 in February 2024.
• Atwood-Edminster Trust dtd 4-2-2000 (Brian G. Atwood, current board member and former Chairman/CEO, is a trustee) purchased 1,002 shares of Series A Preferred Stock for $1,002,000 in February 2024.
• Chris Ehrlich (current Chairman and CEO) purchased 275 shares of Series A Preferred Stock for $275,000 in February 2024.
• Atwood-Edminster Trust dtd 4-2-2000 and GVN, LLC (managed by Brian G. Atwood and Lynne H. Edminster) purchased 25,510 pre-funded warrants and 25,510 February 2025 Common Warrants for $999,992 in February 2025.
• A related party investor (majority shareholder of Stella Diagnostics, Inc. with board representation) was involved in the exchange of Stella Series D Preferred Stock for the company's Series D Preferred Stock on April 22, 2025, and subsequently resold the Stella shares to this related party.
• Incurred consulting fees of $190,000 during the nine months ended September 30, 2025, and $75,000 during the period from February 14, 2024, to September 30, 2024, to members of the company's board of directors.

Stakeholder Impact

• Shareholders face significant dilution risk due to ongoing capital raises through preferred stock and warrants with potentially unfavorable conversion terms and down-round provisions. The Nasdaq delisting reduces liquidity and market visibility. Increased net losses and going concern doubt negatively impact shareholder value.
• Employees may be impacted by the company's financial instability and 'going concern' warning, potentially affecting morale and retention, despite the existence of stock-based compensation plans.
• Future customers are indirectly impacted as the company is in early clinical development; delays in R&D due to funding issues could delay product availability.
• Creditors and suppliers face potential risks regarding timely payment due to the company's liquidity concerns and increased accounts payable, although some liabilities have been settled.
• Regulatory authorities, particularly the SEC, may increase scrutiny due to identified material weaknesses in internal controls and a history of untimely SEC filings, potentially leading to further compliance challenges.

Next Steps

• Continue research and development activities and clinical development of product candidates.
• Seek additional funding to maintain current operations and R&D activities.
• Remediate material weaknesses in internal control over financial reporting by recruiting qualified accounting personnel, engaging third-party consultants, and implementing enhanced financial reporting systems.
• Seek to trade shares of common stock on the OTC Markets.
• Potentially pursue orphan drug designation for additional product candidates.
• Seek stockholder approval for the issuance of Series E Conversion Shares at a conversion price below the Series E Conversion Price (by December 31, 2025).
• File a registration statement with the SEC to register for resale the Common Stock issuable upon conversion of the Series E Preferred Stock.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by a substantial and rapidly increasing net loss, a significant accumulated deficit, and an explicit 'going concern' warning. The recent Nasdaq delisting is a major blow, severely limiting market liquidity and access to capital, which is critical for an early-stage biotech. The identified material weaknesses in internal controls further undermine confidence in financial reporting. While clinical progress and FDA designations are positive, they are overshadowed by the overwhelming financial instability and operational deficiencies. The high risk of further dilution from ongoing capital raises with potentially unfavorable terms, coupled with the uncertainty of future funding, makes this a highly speculative and risky investment. A seasoned investor would likely view the current situation as unsustainable without a significant, immediate, and successful turnaround in financial health and governance, which is not evident in this filing.

Keywords

CERO Therapeutics, Biotechnology, Immunotherapy, Cancer Therapy, T-cell Therapeutics, CER-1236, Acute Myelogenous Leukemia, AML, Orphan Drug Designation, Fast Track Designation, Nasdaq Delisting, OTC Pink Sheets, Financial Results, Net Loss, Capital Raise, Equity Line of Credit, Preferred Stock, Warrants, Clinical Trials, FDA Approval, Risk Factors, Internal Controls, Going Concern